Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Mark Andrew Schattner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0008-0448-2736; OpenAlex author ID A5040211001. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 trial · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  2. A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-3189↗
  3. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  4. Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication. Co-author DOI 10.1016/j.pan.2024.05.515↗
  5. Evaluation of the reporting quality of clinical practice guidelines on pancreatic cancer using the RIGHT checklist. Co-author DOI 10.21037/atm-21-2644↗
  6. The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. First author DOI 10.1016/j.hpb.2017.09.001↗
  7. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Co-author DOI 10.1158/1078-0432.ccr-17-0899↗
  8. Interventional endoscopy in the diagnosis and management of pancreatic adenocarcinoma. Last author DOI 10.21037/cco.2017.12.02↗
  9. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Co-author DOI 10.1038/ajg.2011.65↗

Trials 1

  1. Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Pa… Principal investigator NCT02340728↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anna M. Varghese · 4 shared papers, 2017–2026 · strength 0.61
  2. Eileen Mary O'Reilly · 4 shared papers, 2017–2026 · strength 0.61
  3. Kenneth H. Yu · 4 shared papers, 2017–2026 · strength 0.61
  4. Wungki Park · 3 shared papers, 2024–2026 · strength 0.57
  5. Marinela Capanu · 2 shared papers, 2024–2025 · strength 0.35
  6. Alice Chia-Chi Wei · 2 shared papers, 2024–2025 · strength 0.35
  7. William R. Jarnagin · 4 shared papers, 2011–2025 · strength 0.33
  8. Olca Baştürk · 2 shared papers, 2017–2025 · strength 0.22
  9. Christine A. Iacobuzio–Donahue · 2 shared papers, 2017–2025 · strength 0.22
  10. Milind M. Javle · 1 shared paper, 2026 · strength 0.22
  11. Talia Golan · 1 shared paper, 2026 · strength 0.22
  12. Celina Ang · 1 shared paper, 2026 · strength 0.22
  13. Brinda Alagesan · 1 shared paper, 2026 · strength 0.22
  14. Manoop S. Bhutani · 1 shared paper, 2026 · strength 0.22
  15. Hans Gerdes · 2 shared papers, 2011–2024 · strength 0.20
  16. Fergus Keane · 1 shared paper, 2024 · strength 0.18
  17. Isha Singh · 1 shared paper, 2024 · strength 0.18
  18. Zsofia Kinga Stadler · 1 shared paper, 2025 · strength 0.17
  19. David Paul Kelsen · 1 shared paper, 2025 · strength 0.17
  20. Fiyinfolu O. Balogun · 1 shared paper, 2025 · strength 0.17
  21. Peter J. Allen · 3 shared papers, 2011–2018 · strength 0.16
  22. Vinod P. Balachandran · 2 shared papers, 2017–2018 · strength 0.13
  23. Asim S. Khokhar · 1 shared paper, 2017 · strength 0.12
  24. Matthew H. G. Katz · 1 shared paper, 2021 · strength 0.11
  25. Shuzhang Du · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.